MedTrace Logo

Study of Acamprosate in Fragile x Syndrome

NCT01911455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-02-03

No results posted yet for this study

Summary

In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).

Conditions

  • Fragile X Syndrome

Interventions

DRUG

acamprosate

DRUG

Placebo

Sponsors & Collaborators

  • Rush University Medical Center

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Craig Erickson, MD · Children's Hospital Medical Center, Cincinnati

  • Elizabeth Berry-Kravis, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
23 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-27
Primary Completion
2018-11-08
Completion
2018-11-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01911455 on ClinicalTrials.gov